Ozempic for Kidney Disease: What the FLOW Trial Proved
The first GLP-1 ever approved for kidney protection. FLOW trial results, eligibility, and how semaglutide fits alongside SGLT2 inhibitors and ARBs in modern CKD care.
In January 2025, the FDA approved Ozempic (semaglutide) for a new indication: reducing the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. It's the first — and still only — GLP-1 medication approved for kidney outcomes, based on the landmark FLOW trial.
For the roughly 14.8 million Americans who have both type 2 diabetes and CKD, this approval represents a genuine addition to the toolkit. The FLOW trial stopped early for efficacy. The risk reductions are substantial. And the implications for how nephrology and obesity medicine work together are only beginning to be worked out.
What FLOW Measured
FLOW was a Phase 3b, international, randomized, double-blind, placebo-controlled superiority trial conducted at approximately 400 sites in 28 countries. 3,533 adults with type 2 diabetes and CKD were randomized 1:1 to receive either Ozempic 1 mg weekly (n=1,767) or placebo (n=1,766) added to standard of care.
Inclusion criteria defined a specific CKD population:
- eGFR 50–75 mL/min/1.73m² with UACR >300 and <5000 (reduced kidney function with significant albuminuria), OR
- eGFR 25–<50 mL/min/1.73m² with UACR >100 and <5000 (more advanced CKD with at least some albuminuria)
The primary endpoint was a five-component composite:
- Sustained ≥50% reduction in eGFR from baseline
- Sustained eGFR <15 mL/min/1.73m² (i.e., kidney failure)
- Initiation of chronic kidney replacement therapy (dialysis or transplant)
- Kidney-related death
- Cardiovascular death
FLOW was stopped early by the Independent Data Monitoring Committee after meeting pre-specified efficacy criteria — a rare outcome that indicates the benefit was large enough that continuing the trial would have withheld treatment from the placebo group unethically.
The Results
| Outcome | Semaglutide | Placebo | Risk Reduction |
|---|---|---|---|
| Primary composite | 331 events | 410 events | 24% |
| eGFR slope (annual) | Slower decline | Faster decline | 1.16 ml/min/year difference |
| MACE | 212 events | 254 events | 18% |
| All-cause death | — | — | 20% |
The 24% reduction in the primary composite (HR 0.76 [95% CI: 0.66, 0.88], p=0.0003) was statistically significant across all five components. All secondary outcomes — eGFR slope, MACE, all-cause mortality — also reached significance in semaglutide's favor.
Results were published in the New England Journal of Medicine (Perkovic et al., May 2024) and updated later that year.
Kidney disease progression is typically quantified by the rate of eGFR decline per year. A difference of 1.16 ml/min/1.73m² per year may sound small, but over a decade it compounds into roughly 12 points of eGFR preservation — often the difference between remaining off dialysis and requiring renal replacement therapy. For patients who are already in the middle stages of CKD, this is a clinically meaningful long-term change.
How It Works (Mechanism)
The kidney benefit of semaglutide is thought to involve multiple overlapping pathways:
- Improved glycemic control: Better glucose management reduces glomerular hyperfiltration and microvascular damage
- Blood pressure reduction: Modest but consistent systolic BP decreases reduce intraglomerular pressure
- Weight loss: Reduces metabolic demand on kidneys and improves many cardiovascular risk factors that compound CKD
- Direct anti-inflammatory effects: Semaglutide reduces high-sensitivity CRP and other inflammatory markers that drive CKD progression
- Cardiorenal-metabolic axis improvements: CKD, heart failure, and metabolic dysfunction interact bidirectionally — improvements in one typically benefit the others
Post-hoc analyses suggest the kidney benefit is not fully explained by glycemic control or weight loss alone, meaning some of the effect appears to be direct kidney protection through mechanisms that are still being characterized.
Who Qualifies Under the CKD Indication
Per the January 2025 FDA label expansion, Ozempic is approved for adults with both:
- Type 2 diabetes mellitus
- Chronic kidney disease (defined by eGFR and UACR thresholds matching the FLOW inclusion criteria)
The label covers Ozempic at 0.5 mg, 1 mg, and 2 mg doses. The FLOW trial specifically used 1 mg weekly, which is the dose most directly supported by the efficacy data.
Important distinction: Wegovy (also semaglutide, at 2.4 mg weekly for obesity) does not carry the CKD indication. The CKD label is specific to the diabetes formulations. Patients on Wegovy for obesity who also have T2D and CKD are getting the same molecule but at a different labeled indication.
How It Fits With Other Kidney Medications
For adults with T2D and CKD, several other drug classes have established kidney protection benefits:
| Drug Class | Example | Kidney Benefit |
|---|---|---|
| SGLT2 inhibitors | Empagliflozin, Dapagliflozin | Strong — reduce progression of CKD in diabetics and non-diabetics |
| ACE inhibitors / ARBs | Lisinopril, Losartan | Foundational — standard of care for diabetic nephropathy |
| Nonsteroidal MRAs | Finerenone | Kidney and cardiovascular outcomes in T2D + CKD |
| GLP-1 RAs | Semaglutide (Ozempic) | New — FLOW trial data |
Current nephrology practice generally uses combination therapy. A patient with T2D and CKD might be on an SGLT2 inhibitor, an ARB, finerenone, and now potentially semaglutide — not because one doesn't work, but because each addresses different mechanisms and the effects appear additive.
FLOW allowed patients to be on SGLT2 inhibitors at baseline, and about 15–16% of participants were. Semaglutide's benefit was consistent regardless of SGLT2 inhibitor use, suggesting the two drug classes work through different mechanisms and can be combined. If you're on an SGLT2 inhibitor (e.g., Jardiance, Farxiga) and have T2D + CKD, adding semaglutide is clinically reasonable and supported by FLOW subgroup data.
What This Means for Obesity Patients
If you have obesity and happen to also have T2D with CKD, the clinical picture has changed meaningfully:
- Dual-purpose prescription: A single semaglutide prescription can address obesity, glycemic control, cardiovascular risk, and now kidney progression simultaneously.
- Coverage pathway: Insurers that exclude GLP-1s for weight loss may cover Ozempic for CKD + T2D — the medication is identical; the clinical indication differs.
- Dosing considerations: Obesity dosing (Wegovy 2.4 mg) vs. CKD dosing (Ozempic 1 mg) are labeled differently. Your prescriber may need to choose which indication to prioritize for formulary purposes.
If You Have CKD Without Diabetes
FLOW specifically enrolled patients with T2D + CKD. The FDA approval is limited to that population. Whether semaglutide benefits non-diabetic CKD is an open question being studied in ongoing trials.
For now, non-diabetic CKD patients on Wegovy (for obesity) or other GLP-1s may experience some kidney protection as a secondary effect, but the evidence base is not yet there to make a labeled claim. Standard CKD management — ACE inhibitors/ARBs, SGLT2 inhibitors (now labeled for CKD regardless of diabetes status with empagliflozin and dapagliflozin), and blood pressure control — remains the foundation.
Need FDA-approved brand-name medication?
Sesame Care connects you with licensed U.S. physicians who prescribe brand-name Wegovy and Zepbound.
Side Effects and Kidney-Specific Considerations
The FLOW safety profile was consistent with prior semaglutide trials. Some specific kidney-related considerations:
- Acute kidney injury risk during GI side effects: Severe nausea, vomiting, or diarrhea can cause dehydration, which in CKD patients can precipitate acute kidney injury. Aggressive hydration during GI symptom episodes is particularly important.
- Diuretic and contrast interactions: Patients on diuretics should discuss dose adjustments during GLP-1 initiation. IV contrast studies require extra caution in CKD patients on GLP-1 therapy due to additive AKI risk.
- Renal dose adjustments: Semaglutide does not require dose adjustment for renal impairment, but titration may need to be slower in patients with more advanced CKD to manage side effect tolerance.
Questions for Your Nephrologist or PCP
- Based on my eGFR and UACR, do I meet the criteria for the FLOW indication?
- Am I already optimized on SGLT2 inhibitors, ACEi/ARBs, and finerenone (if appropriate)?
- How will we coordinate glycemic goals between endocrinology and nephrology?
- What's the hydration plan if I experience GI side effects during titration?
- How often will we monitor eGFR and UACR during semaglutide therapy?
The Bottom Line
The FLOW trial and January 2025 FDA approval add a significant new tool for treating diabetic kidney disease. A 24% reduction in kidney disease progression and death is a large effect — comparable to the benefits shown by SGLT2 inhibitors, which transformed CKD care in the early 2020s. For patients with T2D and CKD, semaglutide is now part of a multi-drug protective strategy alongside SGLT2 inhibitors, ARBs, and finerenone. The medications work through different mechanisms and appear additive. Whether the kidney benefits extend to non-diabetic CKD is still being studied. For now, this indication is a major step forward for a condition that affects nearly 40% of people with type 2 diabetes.